Prior research found that the simultaneous delivery of celecoxib (COX-2 inhibitor) and PD-1 inhibitor to tumor-bearing mice enhanced T-cell immunity against cancer cells and decreased tumor-induced inflammation and angiogenesis [6]. The gene discussed is PDCD1; the disease is neoplasm.